BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+7.17%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$1.84B
AUM Growth
+$1.84B
(+13%)
Cap. Flow
+$223M
Cap. Flow
% of AUM
12.13%
Top 10 Holdings %
Top 10 Hldgs %
45.79%
Holding
65
New
8
Increased
22
Reduced
13
Closed
3
Top Buys
| 1 |
Relay Therapeutics
RLAY
|
$144M |
| 2 |
Kymera Therapeutics
KYMR
|
$85M |
| 3 |
Cytokinetics
CYTK
|
$71.9M |
| 4 |
Revolution Medicines
RVMD
|
$45.3M |
| 5 |
Repare Therapeutics
RPTX
|
$34.5M |
Top Sells
| 1 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
$88.8M |
| 2 |
argenx
ARGX
|
$57.9M |
| 3 |
Kura Oncology
KURA
|
$39.4M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$32.6M |
| 5 |
Black Diamond Therapeutics
BDTX
|
$16M |
Sector Composition
| 1 | Healthcare | 98.4% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Relay Therapeutics
RLAY
$619M
| $144M | 7.84% | +3,378,380 | New | +$144M |
|
|
SWTX
2
DELISTED
SpringWorks Therapeutics
SWTX
| $97.9M | 5.33% | 2,053,991 -232,900 | -10% | -$11.1M |
|
|
3
Repare Therapeutics
RPTX
$71.7M
| $94.3M | 5.14% | 3,064,734 +1,120,188 | +58% | +$34.5M |
|
|
4
Kymera Therapeutics
KYMR
$2.95B
| $85M | 4.63% | +2,630,658 | New | +$85M |
|
5
Xencor
XNCR
$580M
| $80.2M | 4.37% | 2,068,098 | – | – |
|
6
Xoma
XOMA
$392M
| $78.8M | 4.29% | 4,182,243 +156,086 | +4% | +$2.94M |
|
|
7
Revolution Medicines
RVMD
$7.1B
| $73.1M | 3.98% | 2,101,049 +1,302,763 | +163% | +$45.3M |
|
|
8
Cytokinetics
CYTK
$4.23B
| $71.9M | 3.92% | +3,323,051 | New | +$71.9M |
|
9
Merus
MRUS
$4.98B
| $67.7M | 3.69% | 5,645,571 +555,000 | +11% | +$6.66M |
|
10
AC Immune
ACIU
$205M
| $47.9M | 2.61% | 9,818,758 -1,500,000 | -13% | -$7.32M |
|
11
Protagonist Therapeutics
PTGX
$3.67B
| $46.4M | 2.53% | 2,372,288 +5,000 | +0.2% | +$97.8K |
|
|
12
Kura Oncology
KURA
$686M
| $45.6M | 2.48% | 1,489,112 -1,286,770 | -46% | -$39.4M |
|
13
Celldex Therapeutics
CLDX
$1.47B
| $45.5M | 2.48% | 3,066,797 +326,797 | +12% | +$4.85M |
|
|
14
argenx
ARGX
$43.6B
| $44.5M | 2.42% | 169,600 -220,400 | -57% | -$57.9M |
|
15
Arcus Biosciences
RCUS
$1.13B
| $44.5M | 2.42% | 2,597,222 +714,500 | +38% | +$12.2M |
|
16
Immunovant
IMVT
$2.56B
| $42.2M | 2.3% | 1,198,427 +109,948 | +10% | +$3.87M |
|
17
IDEAYA Biosciences
IDYA
$2.15B
| $40.5M | 2.21% | 3,226,769 | – | – |
|
18
Replimune Group
REPL
$422M
| $38.9M | 2.12% | 1,691,834 -623,219 | -27% | -$14.3M |
|
19
Xenon Pharmaceuticals
XENE
$2.98B
| $38.7M | 2.11% | 3,499,346 -17,505 | -0.5% | -$194K |
|
20
Forte Biosciences
FBRX
$137M
| $37.7M | 2.05% | 777,553 -201,304 | -21% | -$9.77M |
|
|
FPRX
21
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $37.6M | 2.05% | 8,009,353 +21,300 | +0.3% | +$100K |
|
22
Syndax Pharmaceuticals
SNDX
$1.41B
| $36.5M | 1.99% | 2,470,678 | – | – |
|
|
23
Ionis Pharmaceuticals
IONS
$6.79B
| $34.9M | 1.9% | 735,055 -687,787 | -48% | -$32.6M |
|
24
Sutro Biopharma
STRO
$72.7M
| $31M | 1.69% | 3,087,195 +718,803 | +30% | +$7.22M |
|
25
ALX Oncology
ALXO
$62.7M
| $24.1M | 1.31% | +638,928 | New | +$24.1M |
|